News about Global Pharma

FDA Approves Novel Treatment for Hemophilia A or B

The FDA has approved Qfitlia (fitusiran) for routine prophylaxis in hemophilia A and B patients aged 12 and older, offering a less frequent dosing option by targeting antithrombin to enhance clotting and reduce bleeding episodes.

Global Pharma | 29/03/2025 | By Manvi |  309

SSI Hits New Milestone with Cardiac Telesurgery Performed from North to South Across 2,000 Km

Made possible by the advanced SSI Mantra 3 Surgical Robotic System, this landmark procedure bridged a 2,000-kilometer distance between SS Innovations' headquarters in Gurugram and Aster CMI Hospital in Bengaluru with imperceptible latency.

Global Pharma | 29/03/2025 | By Aishwarya |  641

Bio-Thera Signs Exclusive Commercialization Deal with Dr. Reddy's for BAT2206 and BAT2506

Under the agreement, Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506. Dr. Reddy's will be responsible for seeking regulatory approvals as well as commercialization in the licensed territories in Southeast Asia, including Cambodia, Indonesia, Malaysia, Philippines, Thailand, Vietnam.

Global Pharma | 29/03/2025 | By Aishwarya |  284

Curium Acquires Monrol to Expand Lutetium-177 Capacity

Monrol complements and adds to Curium’s extensive research & development (R&D) capabilities as it continues to expand its portfolio and pipeline of innovative theranostic products.

Global Pharma | 29/03/2025 | By Aishwarya |  317

TOMI Environmental Solutions and PBSC to Enhance Disinfection Solutions

Through this OEM agreement, TOMI will now offer pass-through hatches and chambers integrated with iHP, specifically designed for optimized decontamination cycles.

Global Pharma | 29/03/2025 | By Aishwarya |  262

Alumis and Kaken Pharmaceutical to Develop ESK-001 in Dermatology in Japan

Under the terms of the agreement, Alumis will receive USD 40 million in upfront and near-term co-development payments from 2025 to 2026, with the potential to earn up to approximately USD 140 million in additional payments based on the achievement of milestones, and field option payments.

Global Pharma | 28/03/2025 | By Aishwarya |  537

ENTOD and Infigo Eyecare Hospitals to Revolutionise Under-Eye Aesthetics

Periorbital hyperpigmentation (POH) affects a significant portion of the population, with prevalence rates reaching up to 30 percent in India, particularly in individuals with darker skin tones.

Global Pharma | 28/03/2025 | By Aishwarya |  261

Primrose Bio Launches Prima RNApols ExTend to Enhance mRNA Vaccine Manufacturing

Prima ExTend outperforms traditional T7 polymerase by generating higher-quality mRNA with lower dsRNA, eliminating a common challenge in mRNA manufacturing and enhancing downstream purification efficiency.<br />

Global Pharma | 28/03/2025 | By Abha |  482

Mochida Seeks Japan's Approval for Tocilizumab Biosimilar in Partnership with AYUMI

This application is based on the results of a Phase I clinical study conducted in Japan with 110 healthy adults and a Phase III clinical study conducted in Japan with 368 patients with rheumatoid arthritis.

Global Pharma | 28/03/2025 | By Abha |  1082

Shree Ganesh Remedies Embraces Sustainability With 2 MW Solar Plant in Gujarat

Gujarat-based pharmaceutical company Shree Ganesh Remedies Ltd. has commissioned a 2 MW solar power plant in Gujarat, covering 70 percent of its power needs. The project is expected to generate annual savings of approximately INR 2 crore in electricity expenses.

Global Pharma | 27/03/2025 | By Manvi |  345